Adolescent depression and suicide are on the rise, yet effective care is limited by long waitlists and large out-of-pocket costs for therapy, limited pharmacological options, and stigma surrounding mental health.
If Limbix Spark is FDA cleared it will be the first prescription digital therapeutic designed to support adolescents with depression. Spark is a multi-week cognitive behavioral therapy based program focused on the completion of value-based activities that spark feelings of pleasure or mastery.
Limbix is actively creating prescription digital therapeutics (PDTs) to enable doctors to prescribe digital, evidence-based, therapeutic interventions for adolescent mental health.
Limbix creates digital therapeutics with significant input from teenagers who provide us valuable feedback. If you are a teen interested in helping Limbix design thoughtful digital experiences for current and future generations of young people, sign up for our User Research Sessions!Learn More
Limbix relies on clinical experts who provide critical product feedback to help ensure the digital therapeutics we create are evidence-based and beneficial for patients. If you are a physician looking to connect with Limbix to provide your input, please join our Physician Advisory Group.Join Physician Advisory Group